Vantia Therapeutics’ Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect In Phase IIa Trial In Nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output.

More: continued here

Filed under: Clinical Trials on June 30th, 2009